# US 2013/0252998 A1 · Cci-779 formulations for parenteral administration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252998 A1
- Document ID: US20130252998A1
- Status: Published application
- Kind: A1
- Application number: 13/892,389
- Filed: 2013-05-13
- Published: 2013-09-26
- Earliest claimed: 2002-07-30
- Assignees: Wyeth
- Applicants: Wyeth LLC
- Inventors: Joseph T. Rubino; Victoria Siskavich; Maureen M. Harrison; Pooja Gandhi
- Web page: https://patentgrep.com/patent/US20130252998A1

## CPC

- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention provides CCI-779 cosolvent concentrates which are useful in preparing a parenteral formulation of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) following admixture with a diluent.

## Claims

### Claim 1

A method for administering a parenteral CCI-779 formulation to a subject in need thereof, said method comprising:
(i) mixing about 1 to about 25 mg/mL of CCI-779, about 15 to about 60% w/v of dehydrated ethanol, about 0.01 to about 0.1% of d,1-α-tocopherol, about 0.001 to about 0.005% w/v of citric acid, and about 15 to about 60% w/v of propylene glycol to provide a cosolvent concentrate;
(ii) mixing about 15 to about 60% w/v of polysorbate 80, about 15 to 60% w/v of polyethylene glycol 400, and about 15 to about 60% w/v of dehydrated ethanol to provide a diluent;
(iii) mixing said cosolvent concentrate and said diluent; and
(iv) administering the product of step (iii) to said subject.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the ratio of said cosolvent concentrate to diluent is about 1:1.5 to about 1:2.

### Claim 3 (depends on 1)

The method according to claim 1, wherein said parenteral CCI-779 formulation is administered by direct injection.

### Claim 4 (depends on 1)

The method according to claim 1, further comprising:
(v) mixing the product of step (iii) with water.

### Claim 5 (depends on 4)

The method according to claim 4, wherein said water is a sterile infusion fluid.

### Claim 6 (depends on 5)

The method according to claim 5, wherein said parenteral CCI-779 formulation is administered by intravenous infusion.

### Claim 7 (depends on 1)

The method according to claim 1, wherein said cosolvent concentrate comprises about 25% mg/mL CCI-779, about 40% w/v of dehydrated ethanol, about 0.75% w/v of d,1-α-tocopherol, 0.0025% w/v of citric acid, and about 35% w/v propylene glycol.

### Claim 8 (depends on 1)

The method according to claim 1, wherein said diluent comprises 20% w/v of dehydrated ethanol, about 40% w/v of polysorbate 80, and about 40% w/v of polyethylene glycol 400.

### Claim 9

A CCI-779 direct injection fluid, said fluid comprising:
(i) about 1 to about 25 mg/mL of CCI-779;
(ii) about 0.01 to about 0.1% w/v of d,1-α-tocopherol;
(iii) about 0.001 to about 0.005% w/v of citric acid;
(iv) about 15 to about 60% w/v of a combination of dehydrated ethanol and propylene glycol; and
(v) about 15 to about 60% w/v of a combination of polysorbate 80 and polyethylene glycol 400.

### Claim 10 (depends on 9)

The CCI-779 direct injection fluid according to claim 9, wherein the ratio of dehydrated ethanol to propylene glycol in component (vi) is about 1.4:1.

### Claim 11 (depends on 9)

The CCI-779 direct injection fluid according to claim 9, wherein the ratio of polysorbate 80 to polyethylene glycol 400 in component (v) is about 1:1.

### Claim 12 (depends on 9)

The CCI-779 direct injection fluid according to claim 9, wherein the ratio of mixture (iv) to mixture (i) is about 50:1.

### Claim 13 (depends on 9)

The CCI-779 direct injection fluid according to claim 9, wherein the ratio of mixture (vi) to component (i) is about 50:1.

### Claim 14 (depends on 9)

The CCI-779 direct injection fluid according to claim 9, comprising about 1% w/v of CCI-779, about 0.03% w/v of d,1-α-tocopherol, about 0.001% w/v of citric acid, about 28% w/v of dehydrated ethanol, about 20% w/v of propylene glycol, about 24% w/v of polysorbate 80, and about 25% w/v of polyethylene glycol 400.

### Claim 15

A CCI-779 intravenous infusion solution comprising:
(i) about 1 to about 25 mg/mL of CCI-779, about 0.01 to about 0.1% w/v of d,1-α-tocopherol, about 0.001 to about 0.005% w/v of citric acid, about 15 to about 60% w/v of a combination of dehydrated ethanol and propylene glycol, and about 15 to about 60% w/v of a combination of polysorbate 80 and polyethylene glycol 400; and
(ii) a sterile infusion fluid.

### Claim 16 (depends on 15)

The CCI-779 intravenous infusion solution according to claim 15, wherein the ratio of dehydrated ethanol to propylene glycol is about 1.4:1.

### Claim 17 (depends on 15)

The CCI-779 intravenous infusion solution according to claim 15, wherein the ratio of polysorbate 80 to polyethylene glycol 400 is about 1:1.

### Claim 18 (depends on 15)

The CCI-779 intravenous infusion solution according to claim 15, wherein the ratio of the combination of dehydrated ethanol and propylene glycol to CCI-779 is about 50:1.

### Claim 19 (depends on 15)

The CCI-779 intravenous infusion solution according to claim 15, wherein the ratio of the combination of polysorbate 80 and polyethylene glycol 400 to CCI-779 is about 50:1.

### Claim 20 (depends on 15)

The CCI-779 intravenous infusion solution according to claim 15, wherein said component (i) comprises about 1% w/v of CCI-779, about 0.03% w/v of d,1-α-tocopherol, about 0.001% w/v of citric acid, about 28% w/v of dehydrated ethanol, about 20% w/v of propylene glycol, about 24% w/v of polysorbate 80, and about 25% w/v of polyethylene glycol 400.

### Claim 21

A method of solubilizing CCI-779 in a solution, said method comprising mixing about 1 to about 25 mg/mL of CCI-779, about 0.01 to about 0.1% w/v of d,1-α-tocopherol, about 0.001 to about 0.005% w/v of citric acid, about 15 to about 60% w/v of a combination of dehydrated ethanol and propylene glycol, and about 15 to about 60% w/v of a combination of polysorbate 80 and polyethylene glycol 400.

### Claim 22

A method of stabilizing a solution comprising CCI-779, said method comprising mixing about 1 to about 25 mg/mL of said CCI-779 with about 15 to about 60% w/v of dehydrated ethanol, about 0.01 to about 0.1% of d,1-α-tocopherol, about 0.001 to about 0.005% w/v of citric acid, and about 15 to about 60% w/v of propylene glycol.

### Claim 23

A method of stabilizing a solution comprising CCI-779, said method comprising mixing about 1 to about 25 mg/mL of said CCI-779 with about 0.01 to about 0.1% w/v of d,1-α-tocopherol, about 0.001 to about 0.005% w/v of citric acid, about 15 to about 60% w/v of a combination of dehydrated ethanol and propylene glycol, and about 15 to about 60% w/v of a combination of polysorbate 80 and polyethylene glycol 400.

### Claim 24

A method of preventing precipitation of CCI-779 in an aqueous infusion solution or blood, said method comprising:
(i) mixing about 1 to about 25 mg/mL of CCI-779, about 15 to about 60% w/v of dehydrated ethanol, about 0.01 to about 0.1% of d,1-α-tocopherol, about 0.001 to about 0.005% w/v of citric acid, and about 15 to about 60% w/v of propylene glycol to provide a cosolvent concentrate;
(ii) mixing about 15 to about 60% w/v of polysorbate 80, about 15 to 60% w/v of polyethylene glycol 400, and about 15 to about 60% w/v of dehydrated ethanol to provide a diluent;
(iii) mixing said cosolvent concentrate and said diluent; and
(iv) adding the product of step (iii) to said aqueous infusion solution or blood.
